Recent Updates
Recently added Catalysts
NVS Positive Sentiment

CAS announces collaboration with Novartis to advance AI-ready reaction informatics

Key Takeaway: CAS has announced a collaboration with Novartis Biomedical Research to enhance reaction data accessibility through AI-enabled research. This partnership will provide Novartis with an integrated platform for searching and analyzing proprietary and curated reaction data. The initiative aims to streamline drug discovery workflows and improve the efficiency of data utilization in research.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration enhances reaction data accessibility for researchers.
  • Integration of AI-ready resources supports advanced drug discovery.
  • Customized discovery platform improves data search and analysis.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+14%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Iscalimab
Phase 2 · Sjögren's Syndrome

Full Press Release Details

Researchers will gain an integrated synthetic data foundation and an advanced custom search platform to support reaction data discovery and analysis
COLUMBUS, Ohio, Sept. 29, 2026 /PRNewswire/ -- CAS, a division of the American Chemical Society, today announced a collaboration with Novartis Biomedical Research focused on enhancing reaction data accessibility and supporting AI-enabled research. The initiative will leverage CAS unique scientific data curation expertise and science-smart technology to give Novartis researchers integrated, searchable access to proprietary experimental reaction data alongside more than 160 million+ scientist-curated reactions from the authoritative CAS Content Collection™.
Scientific research generates valuable reaction data stored across a variety of research systems and repositories, including electronic lab notebooks, reports, shared drives, and partner platforms. Bringing information from these sources together can help researchers more efficiently discover, access, and analyze reaction data across the research enterprise. Foundational to this collaboration is the application of CAS data transformation services, via CAS Intelligence Hub SM, to organize and standardize Novartis' extensive collection of experimental reaction data, helping make these valuable research data assets more readily accessible for computational research, machine learning, and AI applications.
"This exciting collaboration reflects the critical importance of a strong scientific data infrastructure, alongside domain-specific technology and expertise, to enable today's rapidly evolving drug discovery workflows," said Tim Wahlberg, Interim President, CAS. "We are pleased to extend our long-standing relationship with Novartis to help make this data a more accessible and valuable AI-ready resource."
As part of this project, CAS will also collaborate with Novartis to develop a customized discovery platform built on the CAS SciFinder® architecture. This platform is designed to enable Novartis researchers to search, analyze, and cross-reference their enriched internal reaction data and CAS data simultaneously. By addressing a long-standing challenge of efficiently and comprehensively searching internal and external data together, this effort also lays the foundation for future CAS platform capabilities, including large language models and agentic AI.

About CAS

CAS connects the world's scientific knowledge to accelerate breakthroughs that improve lives. We are the scientific data intelligence partner empowering global innovators to capture the promise of AI and achieve real-world results. CAS builds the world's largest collection of scientist-curated data. That foundation underpins our portfolio of science-smart insights platforms and integrates with R&D workflows for more confident decisions and reliable predictions. As a pioneer at the intersection of scientific data and AI-driven discovery, CAS enables leaders in life sciences, chemistry, and materials with the unique capabilities and expertise that deliver transformative innovation. CAS is a division of the American Chemical Society. Connect with us at cas.org.

Frequently Asked Questions

What is the goal of the CAS and Novartis collaboration?

The collaboration aims to enhance reaction data accessibility and support AI-enabled research.

How will CAS improve Novartis' reaction data?

CAS will organize and standardize Novartis' experimental reaction data for better accessibility.

What technology will be used in the collaboration?

The collaboration will utilize CAS Intelligence Hub and a customized discovery platform.

What is the significance of this collaboration?

It addresses challenges in efficiently searching and analyzing internal and external reaction data.

Last updated: Sep 29, 2026